ArticleThe British journal of dermatology2019

A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.

V P Werth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.